Dexmedetomidine: Pharmacology and Clinical Use

Quick Answer

Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with sedative, anxiolytic, and analgesic properties. Mechanism: Acts on alpha-2A receptors in locus coeruleus (sedation), spinal cord (analgesia), and peripheral presynaptic terminals (reduced catecholamine release → sympatholysis). Pharmacokinetics: Rapid distribution (t½α 6 minutes), context-sensitive half-time 30-60 minutes after 4 hours, hepatic glucuronidation and CYP2A6 metabolism, 94% protein bound. Loading dose: 1 μg/kg over 10 minutes (reduces hypotension), maintenance: 0.2-0.7 μg/kg/hour. Unique properties: Analgesia without respiratory depression (maintains CO₂ response), "cooperative sedation" (arousable, follows commands), reduces opioid requirements 30-50%. Side effects: Bradycardia (dose-dependent), hypotension (initial then stabilizes), dry mouth. Clinical uses: ICU sedation (weaning from ventilation), awake craniotomy, procedural sedation (colonoscopy, cardiac catheterization), multimodal analgesia adjunct, alcohol withdrawal. [1-10]

Pharmacology

Chemical Structure

Structure:

• Class: Imidazole derivative (structurally related to clonidine but more selective)
• Molecular weight: 236.7 Da (free base), 419.0 Da (hydrochloride salt)
• Selectivity: Alpha-2:alpha-1 = 1620:1 (vs clonidine 220:1)
• Highly selective: Alpha-2A receptor subtype predominates effects

Mechanism of Action

Alpha-2 Adrenergic Receptors:

• G-protein coupled receptors (Gi/o family)
• Mechanism: Activate G-protein → inhibit adenylate cyclase → ↓cAMP → ↓protein kinase A → multiple downstream effects
• Subtypes:
  • Alpha-2A: Sedation (locus coeruleus), analgesia (spinal cord), neuroprotection
  • Alpha-2B: Vasoconstriction (vascular smooth muscle), antishivering
  • Alpha-2C: Modulates sympathetic outflow, pain modulation

Site-Specific Actions:

1. Locus Coeruleus (Brainstem):

• Primary site for sedation
• Mechanism: Alpha-2A agonism → hyperpolarizes noradrenergic neurons → reduced firing
• Effect: Sedation resembling natural sleep (non-REM), easily arousable
• Cooperative sedation: Patient can follow commands, pain does not awaken

2. Dorsal Horn of Spinal Cord:

• Primary site for analgesia
• Mechanism: Presynaptic inhibition of substance P release, postsynaptic hyperpolarization
• Effect: Spinally-mediated analgesia (reduces opioid requirements)

3. Peripheral Presynaptic Terminals:

• Primary site for sympatholysis
• Mechanism: Negative feedback on norepinephrine release
• Effect: Reduced heart rate, BP (initially), decreased stress response

4. Vascular Smooth Muscle:

• Low doses: Reduced sympathetic tone → vasodilation → ↓BP
• High doses: Alpha-2B mediated vasoconstriction (less prominent with dexmedetomidine than clonidine)

Pharmacokinetics

Administration Routes:

• IV: 100% bioavailability
• IM: Rapid absorption
• Intranasal: Bioavailability ~65%, rapid (used in pediatrics)
• Oral: Bioavailability 15-20% (extensive first-pass), not used
• Buccal: Used in pediatrics

Distribution:

• Volume of distribution (Vd): 1.5-2.5 L/kg
• Protein binding: 94% (albumin and α1-acid glycoprotein)
• Distribution half-life (t½α): 6 minutes (rapid)
• Lipophilic: Crosses blood-brain barrier readily
• Redistribution: Rapid from brain to periphery

Metabolism:

• Primary: Hepatic glucuronidation (UDP-glucuronosyltransferase, UGT)
• Secondary: CYP2A6 oxidation
• Metabolites: Inactive glucuronide conjugates
• No active metabolites: Important advantage
• First-pass: High (80%) - explains low oral bioavailability

Excretion:

• Route: Renal (95% as metabolites, 5% unchanged)
• Elimination half-life (t½β): 2-2.5 hours
• Clearance: 30-50 mL/kg/min (high)
• Context-sensitive half-time:
  • 1-hour infusion: 30 minutes
  • 4-hour infusion: 60 minutes
  • Minimal accumulation (linear kinetics)

Factors Affecting Pharmacokinetics:

Organ Dysfunction:

• Hepatic impairment: Reduced clearance (40-50% dose reduction recommended)
• Renal impairment: Minimal effect (metabolites inactive, but may accumulate)
• Safe in: Renal failure (no active metabolites)

Age:

• Elderly: Increased sensitivity, reduce loading dose to 0.5 μg/kg
• Pediatrics: Similar pharmacokinetics, reduced doses (0.5-1 μg/kg loading)
• Neonates: Limited data, prolonged elimination

Obesity:

• Dosing: Lean body weight (lipophilic but high clearance)

Pharmacodynamics

Onset and Duration:

• Onset after loading: 5-10 minutes
• Peak effect: 15-30 minutes
• Duration after stopping: 30-60 minutes (short context-sensitive half-time)
• Steady state: 10-20 minutes after starting infusion

Dose-Response:

• 0.2-0.3 μg/kg/hour: Light sedation (RASS -1 to -2)
• 0.4-0.6 μg/kg/hour: Moderate sedation (RASS -2 to -3)
• 0.7-1.0 μg/kg/hour: Deep sedation (RASS -3 to -4)
• >1.0 μg/kg/hour: Increasing bradycardia and hypotension risk

Central Nervous System:

Sedation:

• Mechanism: Alpha-2A in locus coeruleus
• Quality: "Cooperative" or "arousable"
  • Patient can open eyes, follow simple commands
  • Returns to sleep when not stimulated
  • Resembles natural sleep (non-REM)
  • Different from GABAergic sedation (propofol, benzodiazepines)
• Respiratory drive: Preserved (minimal effect on ventilation)
  • CO₂ response maintained
  • Upper airway tone maintained (less obstruction than other sedatives)
  • Can breathe spontaneously even at high doses
• Neuroprotection: Reduces CMRO₂, anti-inflammatory, anti-apoptotic (experimental)

Analgesia:

• Mechanism: Alpha-2A in dorsal horn of spinal cord
• Modality: Neuropathic and nociceptive pain
• Potency: Reduces opioid requirements 30-50%
• Synergistic: With opioids, local anaesthetics
• Route: Works spinally (epidural synergy)

Anxiolysis:

• Calm, relaxed state
• No euphoria or dysphoria

Cardiovascular System:

Heart Rate:

• Bradycardia: Dose-dependent, primary effect
• Mechanism: Reduced sympathetic tone, increased vagal tone (indirect)
• Magnitude: 10-20% reduction (HR 50-70 typical)
• Risk factors: Beta-blockers, high doses, young patients, high vagal tone
• Clinical significance: Usually well-tolerated, improves myocardial oxygen supply-demand balance

Blood Pressure:

• Biphasic response:
  1. Initial: Vasodilation → ↓BP (10-20% drop) during loading dose
  2. Maintenance: Stabilizes at slightly below baseline
• Mechanism: Reduced sympathetic vascular tone
• Hypotension risk: Hypovolemia, high loading dose, concurrent antihypertensives
• Hypertension: Rare, usually transient (rebound after stopping)

Cardiac Output:

• Minimal change: Reduced HR offset by increased stroke volume
• Safe in: Cardiac patients (maintains perfusion)

Arrhythmias:

• Reduced: Atrial fibrillation, ventricular ectopy (sympatholysis)
• Increased risk: Bradycardia, heart block (AV nodal slowing)

Respiratory System:

• Ventilation: Preserved (no respiratory depression)
• CO₂ response: Maintained
• Upper airway: Tone maintained (less obstruction than propofol/benzodiazepines)
• Apnoea: Rare even with high doses
• Advantage: Can use with spontaneous breathing

Other Systems:

• Dry mouth: Salivary gland alpha-2 inhibition (common, annoying)
• GI: Reduced motility, nausea (less than opioids)
• Renal: Reduced stress response, potential renoprotection (experimental)
• Endocrine: Reduced cortisol, catecholamines (attenuated stress response)
• Thermoregulation: Shivering (alpha-2B mediated, can be side effect or used for treatment)

Comparison with Clonidine

Clinical Use

ICU Sedation

Primary Indication:

• Prolonged mechanical ventilation (first 24-48 hours, weaning phase)
• Advantages over propofol/midazolam:
  • No respiratory depression (allows spontaneous breathing trials)
  • Cooperative sedation (patient can follow commands, communicate)
  • Analgesic properties (reduces opioid needs)
  • Reduced delirium (vs benzodiazepines)
  • Cardioprotective (reduced catecholamines)
• Advantages over propofol:
  • No lipid load
  • No propofol infusion syndrome risk
  • Context-sensitive half-time stable (minimal accumulation)

Dosing:

• Loading: 1 μg/kg over 10 minutes (optional, reduces hypotension)
  • Can omit in hemodynamically unstable patients
  • Or reduce to 0.5 μg/kg over 10 minutes
• Maintenance: 0.2-0.7 μg/kg/hour
  • Start at 0.4 μg/kg/hour, titrate to RASS target
  • Range: 0.1-1.5 μg/kg/hour (rarely >1.0)
• Duration: Up to 7 days (studied, safe)

Monitoring:

• Sedation: RASS (Richmond Agitation-Sedation Scale) or SAS (Riker)
  • Target: RASS -2 to 0 (light to moderate sedation)
• Cardiovascular: Continuous ECG, BP (bradycardia, hypotension)
• Respiratory: SpO₂, respiratory rate (should be stable)

Weaning:

• Gradual reduction: 0.1 μg/kg/hour every 2-4 hours
• No rebound: Minimal withdrawal (unlike benzodiazepines/opioids)
• Occasional: Tachycardia, hypertension, agitation if abrupt stop

Procedural Sedation

Indications:

• Awake craniotomy: Cooperative sedation, no respiratory depression
• Cardiac catheterization: Hemodynamic stability, reduced catecholamines
• Endoscopy (upper/lower): "Procedure sedation" (arousable, safe)
• Radiological procedures: MRI, CT (claustrophobia)
• Dentistry: Anxiolysis without respiratory depression

Technique:

• Loading: 1 μg/kg over 10 minutes
• Maintenance: 0.2-0.7 μg/kg/hour
• Supplemental: Local anaesthesia (essential - dexmedetomidine has modest analgesia)
• No boluses: Avoid rapid administration (hypotension, oversedation)
• Reversal: Not available (not GABA receptor), support until wears off

Advantages:

• Respiratory safety: Minimal apnoea risk
• Cardiovascular stability: Good for cardiac patients
• Cooperative: Patient can follow commands, open eyes
• Amnestic: Some anterograde amnesia (less than benzodiazepines)

Awake Craniotomy

Special Role:

• Ideal agent: Cooperative sedation, no respiratory depression
• Technique:
  • Loading: 0.5-1 μg/kg over 10 minutes
  • Maintenance: 0.2-0.5 μg/kg/hour
  • Combined with scalp block (local anaesthesia essential)
  • Remifentanil infusion (0.05-0.1 μg/kg/min) for analgesia
• Advantages:
  • Patient can be woken for language/motor testing
  • No airway obstruction
  • Reduced opioid requirements
  • Hemodynamic stability
• Disadvantages:
  • Not deep enough for painful parts (requires local)
  • Bradycardia (if high doses)

Multimodal Analgesia

Role:

• Opioid-sparing: Reduces morphine/fentanyl requirements 30-50%
• Specific indications:
  • Postoperative pain (adjunct to opioids, regional, NSAIDs)
  • Neuropathic pain (spinal cord alpha-2 action)
  • Opioid-tolerant patients
  • Procedures with limited opioid options ( outpatient)

Dosing:

• IV bolus: 0.5-1 μg/kg (postoperative)
• Infusion: 0.2-0.4 μg/kg/hour (intraoperative and postoperative)
• Epidural: Not used (IV works spinally)
• Perineural: Experimental (prolongs block)

Benefits:

• Reduced opioid side effects (nausea, ileus, respiratory depression)
• Better pain scores
• Reduced chronic pain risk (experimental)

Alcohol Withdrawal

Use:

• Alternative to benzodiazepines
• Advantages:
  • Sympatholysis (reduces tachycardia, hypertension, tremors)
  • Sedation without respiratory depression
  • Anxiolysis
  • Shorter duration than clonidine
• Protocol:
  • Loading: 1 μg/kg over 10 minutes
  • Maintenance: 0.2-0.7 μg/kg/hour
  • Taper over 48-72 hours
  • May need additional lorazepam for severe withdrawal
• Not first-line: Benzodiazepines remain first-line, but dex useful adjunct or alternative

Shivering

Mechanism:

• Alpha-2B receptors in thermoregulatory center
• Dose: 0.5-1 μg/kg bolus or 0.2-0.4 μg/kg/hour infusion
• Effective: Reduces shivering (postoperative, hypothermia)
• Alternative: Meperidine (more effective but side effects)

Pediatric Applications

Uses:

• Sedation for procedures: MRI, CT, lumbar puncture
• Preoperative anxiolysis: Intranasal 2-3 μg/kg (15-30 minutes pre-op)
• Postoperative: Reduce emergence delirium, smooth recovery
• ICU: Sedation (less data than adults)

Dosing:

• Intranasal: 2-4 μg/kg (rapid, effective)
• IV: 0.5-1 μg/kg loading, 0.2-0.7 μg/kg/hour
• Buccal: 3-4 μg/kg

Safety:

• Respiratory: Excellent safety profile
• Cardiovascular: Bradycardia more pronounced in children

Obstetrics

Limited Data:

• Placental transfer: Yes (lipophilic)
• Fetal effects: Bradycardia reported (monitor FHR)
• Use: Limited, not first-line
• Potential: Sedation for procedures (amniocentesis), pre-cesarean anxiolysis

Administration and Monitoring

Preparation:

• Concentration: 100 μg/mL (4 mL vials, 400 μg total)
• Dilution: Usually use undiluted or dilute in normal saline
• Infusion: Dedicated line or Y-site compatible

Loading Dose Administration:

• Rate: 1 μg/kg over 10 minutes (critical - not faster)
• Why slow: Reduces hypotension, bradycardia
• Omission: Can omit in hemodynamically unstable (start maintenance only)
• Alternative: 0.5 μg/kg over 10 minutes (elderly, cardiac disease)

Maintenance Infusion:

• Pump: Dedicated syringe or infusion pump
• Rate calculation:
  • 70 kg patient at 0.4 μg/kg/min = 28 μg/min = 1.68 mg/hour
  • 100 μg/mL concentration = 16.8 mL/hour
• Titration: Adjust q15-30 minutes to sedation target

Monitoring:

• Continuous: ECG (bradycardia), BP (hypotension), SpO₂
• Sedation scores: RASS or SAS q1-2h
• Bradycardia treatment: Reduce dose, atropine 0.5 mg if symptomatic
• Hypotension treatment: Fluids, reduce dose, vasopressors if needed

Side Effects and Management

Cardiovascular:

Bradycardia:

• Incidence: 10-30% (dose-dependent)
• Severity: Usually mild (HR 50-60), asymptomatic
• Risk factors: Beta-blockers, high doses, young age, athletes
• Treatment:
  • Reduce infusion rate
  • Atropine 0.5 mg IV if symptomatic or HR <50
  • Glycopyrrolate (alternative)
  • Rarely: Stop infusion
• Contraindication: Severe bradycardia, heart block (second/third degree), sick sinus syndrome (relative)

Hypotension:

• Incidence: 10-30% (usually during loading)
• Mechanism: Vasodilation (reduced sympathetic tone)
• Treatment:
  • Reduce or slow loading dose
  • Fluid bolus
  • Reduce maintenance rate
  • Phenylephrine/ephedrine if needed
  • Rarely requires stopping

Hypertension:

• Rare: Usually transient (early alpha-2B effect or rebound)
• Treatment: Usually self-limited, reduce dose

CNS:

• Oversedation: Reduce dose, support airway (rare)
• Confusion/agitation: Rare, usually in elderly

Other:

• Dry mouth: Very common (50-70%), treat with ice chips
• Nausea: Less than opioids
• Constipation: Less than opioids

Special Populations

Elderly:

• Increased sensitivity: Reduce loading dose to 0.5 μg/kg
• Reduced clearance: Slightly prolonged effect
• Cardiovascular: More bradycardia, hypotension
• CNS: More confusion (rare)

Hepatic Impairment:

• Reduced clearance: 40-50% dose reduction
• Caution: Monitor for prolonged effect

Renal Impairment:

• No active metabolites: Safe
• May accumulate: Metabolites (inactive) may accumulate, minimal effect
• Safe in dialysis: Not dialyzable (highly protein bound)

Cardiac Disease:

• Advantage: Cardioprotective (reduced catecholamines)
• Caution: Bradycardia, AV block (avoid in conduction disease)
• Use: Good for cardiac surgery, catheterization

Pregnancy:

• Category C: Limited data
• Fetal bradycardia: Monitor FHR
• Use: Only if benefit > risk

Obesity:

• Dosing: Lean body weight (lipophilic but high clearance)
• Alternatively: Ideal body weight + 40% of excess weight

ANZCA Primary Exam Focus

Key Concepts

Mechanism:

• Alpha-2 adrenergic agonist (highly selective, 1620:1 alpha-2:alpha-1)
• Sites: Locus coeruleus (sedation), spinal cord (analgesia), peripheral terminals (sympatholysis)
• G-protein coupled receptor (Gi/o) → ↓cAMP

Pharmacokinetics:

• Rapid onset (5-10 min), short half-life (2-2.5 hours)
• Context-sensitive half-time stable (30-60 min)
• Hepatic metabolism (glucuronidation, CYP2A6), no active metabolites
• High protein binding (94%)

Clinical:

• Sedation without respiratory depression ("cooperative sedation")
• Analgesia (reduces opioid requirements 30-50%)
• Bradycardia and hypotension (sympatholysis)
• Dry mouth (very common)

Dosing:

• Loading: 1 μg/kg over 10 min (reduce in elderly/unstable)
• Maintenance: 0.2-0.7 μg/kg/hour

Comparison:

• Clonidine: Less selective (220:1), longer half-life (12-16 hours), more vasoconstriction
• Dexmedetomidine: More selective, shorter, no active metabolites, preferred

Common Exam Questions

"What is the mechanism of action of dexmedetomidine?"

• Selective alpha-2 adrenergic agonist (1620:1 selectivity vs alpha-1)
• Acts on locus coeruleus (sedation), spinal cord (analgesia), peripheral terminals (reduced catecholamine release)
• G-protein coupled receptor → ↓cAMP → hyperpolarization

"What are the advantages of dexmedetomidine over propofol for ICU sedation?"

• No respiratory depression (maintains CO₂ response, airway tone)
• Cooperative sedation (arousable, follows commands)
• Analgesic properties (reduces opioid needs)
• Reduced delirium (vs benzodiazepines)
• Stable context-sensitive half-time (minimal accumulation)
• Cardioprotective (reduced catecholamines)

"Why must the loading dose be given over 10 minutes?"

• Rapid administration causes hypotension (vasodilation from sudden sympatholysis)
• Slower administration allows hemodynamic compensation
• Reduces bradycardia risk

"Compare dexmedetomidine and clonidine."

• Dexmedetomidine: Higher alpha-2 selectivity (1620:1), shorter half-life (2-2.5 hours), faster onset, no active metabolites, primarily IV
• Clonidine: Lower selectivity (220:1), longer half-life (12-16 hours), slower onset, primarily oral, more vasoconstriction

"What is 'cooperative sedation'?"

• Unique to dexmedetomidine (alpha-2A mediated)
• Patient is sedated but easily arousable
• Can follow commands, open eyes when stimulated
• Returns to sleep when not stimulated
• Resembles natural sleep
• Respiratory drive preserved

References

1. ANZCA. Primary Examination Syllabus. Pharmacology Section.
2. Ebert TJ et al. Dexmedetomidine and the cardiovascular system. Anesthesiology. 2000;93(2):382-394.
3. Venn RM et al. Pharmacokinetics of dexmedetomidine. Br J Anaesth. 2002;88(5):669-675.
4. Pandharipande PP et al. Effect of sedation with dexmedetomidine vs lorazepam. JAMA. 2007;298(22):2644-2653.
5. Riker RR et al. Dexmedetomidine vs midazolam for sedation. JAMA. 2009;301(5):489-499.
6. Bekker A et al. The use of dexmedetomidine infusion for awake craniotomy. Anesth Analg. 2001;92(5):1251-1253.
7. De Wolf AM et al. Pharmacokinetics and pharmacodynamics of dexmedetomidine. Anesth Analg. 2001;93(4):863-868.
8. Gertler R et al. Dexmedetomidine: A guide to its use. CNS Drugs. 2001;15(11):851-870.